FactorPad
Build a Better Process

Stock Risk Measures for Reata Pharmaceuticals Inc-A

A quantitative factor review as of September 30, 2021.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: October 05, 2021
See how we arrive at an overall risk score of 70 for RETA below.

/ factorpad.com / stocks / f49dfm.html


An ad-free and cookie-free website.


RETA Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Reata Pharmaceuticals Inc-A. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how RETA stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f49dfm.html


RETA stock risk
REATA PHARMACEUTICALS INC-A stock beta
RETA risk report
RETA f49dfm
RETA risk analysis
RETA volatility
REATA PHARMACEUTICALS INC-A credit risk
RETA liquidity risk
RETA leverage
RETA valuation
RETA systematic risk
RETA specific risk
REATA PHARMACEUTICALS INC-A volatility
RETA analysis
RETA financial ratio

A newly-updated free resource. Connect and refer a friend today.